Treatment of plaque psoriasis with biologics. A meta-analysis of randomized controlled trials;Behandlung der Plaque-psoriasis mit Biologics: Eine Metaanalyse Randomisierter Kontrollierter Studien

Medizinische Klinik

Volumn 104, Issue 2, 2009, Pages 125-136

  Zhang, Zhengguang ^a   Schmitt, Jochen ^a   Wozel, Gottfried ^a   Kirch, Wilhelm ^a  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

Adalimumab; Efalizumab; Etanercept; Infliximab; Meta analysis; Psoriasis vulgaris; Systematic review

Indexed keywords

ADALIMUMAB; EFALIZUMAB; ETANERCEPT; INFLIXIMAB; PLACEBO;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DISEASE SEVERITY; DRUG EFFICACY; DRUG WITHDRAWAL; GERMANY; HUMAN; META ANALYSIS; PSORIASIS VULGARIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SHORT COURSE THERAPY; SYSTEMATIC REVIEW; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; BIOLOGICAL PRODUCTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; EVIDENCE-BASED MEDICINE; HUMANS; IMMUNOGLOBULIN G; PSORIASIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, TUMOR NECROSIS FACTOR;

SCOPUS;

EID: 61849163942     PISSN: 07235003     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00063-009-1024-8     Document Type: Article

References (47)

1. A. Nast I.B. Kopp M,. [. Augustin 2006 S3-guidelines for the therapy of psoriasis vulgaris J Dtsch Dermatol Ges 4 Suppl2 S1 126
2. S.R. Feldman A.B. Fleischer Jr D.M. Reboussin 1997 The economic impact of psoriasis increases with psoriasis severity J Am Acad Dermatol 37 564 9
3. J. Schmitt D.E. Ford 2006 Work limitations and productivity loss are associated with health-related quality of life but not with clinical severity in patients with psoriasis Dermatology 213 102 10
4. S. Sohn O. Schoeffski J. Prinz 2006 Cost of moderate to severe plaque psoriasis in Germany: a multicenter cost-of-illness study Dermatology 212 137 44
5. L. Mallbris O. Akre F. Granath 2004 Increased risk for cardiovascular mortality in psoriasis inpatients but not in outpatients Eur J Epidemiol 19 225 30
6. J.M. Gelfand A.B. Troxel J.D. Lewis 2007 The risk of mortality in patients with psoriasis: results from a population-based study Arch Dermatol 143 1493 9
7. J.M. Schmitt D.E. Ford 2007 Role of depression in quality of life for patients with psoriasis Dermatology 215 17 27
8. K. Reich U. Mrowietz 2007 Treatment goals in psoriasis J Dtsch Dermatol Ges 5 566 74
9. Wozel G, Jahn S, Hrsg. Biologics in der Dermatologie, 2. Aufl. Bremen-London-Boston: Uni-Med, 2006.
10. C. Claes W. Kulp W. Greiner 2006 Therapie der mittelschweren und der schweren Psoriasis GMS Health Technol Assess 2 Doc07
11. C.E. Griffiths C.M. Clark R.J. Chalmers 2000 A systematic review of treatments for severe psoriasis Health Technol Assess 4 1 125
12. Woolacott N, Hawkins N, Mason A, et al. Etanercept and efalizumab for the treatment of psoriasis: a systematic review. Health Technol Assess 2006;10(46).
13. T. Fredriksson U. Pettersson 1978 Severe psoriasis-oral therapy with a new retinoid Dermatologica 157 238 44
14. R. Shikiar B.W. Bresnahan S.P. Stone 2003 Validity and reliability of patient reported outcomes used in psoriasis: results from two randomized clinical trials Health Qual Life Outcomes 1 53
15. A.R. Jadad R.A. Moore D. Carroll 1996 Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17 1 12
16. J. Schmitt G. Wozel 2005 The psoriasis area and severity index is the adequate criterion to define severity in chronic plaque-type psoriasis Dermatology 210 194 9
17. Egger M, Smith GD, Altman DG. Systematic reviews in health care. Meta-analysis in context. London: BMJ, 2003.
18. U. Chaudhari P. Romano L.D. Mulcahy 2001 Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial Lancet 357 1842 7
19. A.B. Gottlieb R. Evans S. Li 2004 Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial J Am Acad Dermatol 51 534 42
20. S.R. Feldman K.B. Gordon M. Bala 2005 Infliximab treatment results in significant improvement in the quality of life of patients with severe psoriasis: a double-blind placebo-controlled trial Br J Dermatol 152 954 60
21. K. Reich F.O. Nestle K. Papp 2005 Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial Lancet 366 1367 74
22. K. Reich F.O. Nestle K. Papp 2006 Improvement in quality of life with infliximab induction and maintenance therapy in patients with moderate-to-severe psoriasis: a randomized controlled trial Br J Dermatol 154 1161 8
23. A. Menter S.R. Feldman G.D. Weinstein 2007 A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis J Am Acad Dermatol 56 31 e1 15
24. C.L. Leonardi J.L. Powers R.T. Matheson 2003 Etanercept as monotherapy in patients with psoriasis N Engl J Med 349 2014 22
25. S.R. Feldman A.B. Kimball G.G. Krueger 2005 Etanercept improves the health-related quality of life of patients with psoriasis: results of a phase III randomized clinical trial J Am Acad Dermatol 53 887 9
26. A.B. Gottlieb R.T. Matheson N. Lowe 2003 A randomized trial of etanercept as monotherapy for psoriasis Arch Dermatol 139 1627 32
27. K.A. Papp S. Tyring M. Lahfa 2005 A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction Br J Dermatol 152 1304 12
28. G.G. Krueger R.G. Langley A.Y. Finlay 2005 Patient-reported outcomes of psoriasis improvement with etanercept therapy: results of a randomized phase III trial Br J Dermatol 153 1192 9
29. S. Tyring A. Gottlieb K. Papp 2006 Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial Lancet 367 29 35
30. S. Tyring K.B. Gordon Y. Poulin 2007 Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis Arch Dermatol 143 719 26
31. N. Cassano F. Loconsole A. Galluccio 2006 Once-weekly administration of high-dosage etanercept in patients with plaque psoriasis: results of a pilot experience (power study) Int J Immunopathol Pharmacol 19 225 9
32. K.B. Gordon K.A. Papp T.K. Hamilton 2003 Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial JAMA 290 3073 80
33. A. Menter K. Gordon W. Carey 2005 Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis Arch Dermatol 141 31 8
34. M. Lebwohl S.K. Tyring T.K. Hamilton 2003 A novel targeted T-cell modulator, efalizumab, for plaque psoriasis N Engl J Med 349 2004 13
35. C.L. Leonardi K.A. Papp K.B. Gordon 2005 Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized phase III trial J Am Acad Dermatol 52 425 33
36. K.A. Papp R. Bressinck S. Fretzin 2006 Safety of efalizumab in adults with chronic moderate to severe plaque psoriasis: a phase IIIb, randomized, controlled trial Int J Dermatol 45 605 14
37. L. Dubertret W. Sterry J.D. Bos 2006 Clinical Experience Acquired with the Efalizumab (Raptiva) (CLEAR) trial in patients with moderate-to-severe plaque psoriasis: results from a phase III international randomized, placebo-controlled trial Br J Dermatol 155 170 81
38. J.P. Ortonne N. Shear S. Shumack 2005 Impact of efalizumab on patient-reported outcomes in high-need psoriasis patients: results of the international, randomized, placebo-controlled phase III Clinical Experience Acquired with Raptiva (CLEAR) trial [NCT00256139] BMC Dermatol 5 13
39. K.B. Gordon R.G. Langley C. Leonardi 2006 Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study J Am Acad Dermatol 55 598 606
40. R. Shikiar M.K. Willian M.M. Okun 2006 The validity and responsiveness of three quality of life measures in the assessment of psoriasis patients: results of a phase II study Health Qual Life Outcomes 4 71
41. R. Shikiar M. Heffernan R.G. Langley 2007 Adalimumab treatment is associated with improvement in health-related quality of life in psoriasis: patient-reported outcomes from a phase II randomized controlled trial J Dermatol Treat 18 25 31
42. A. Menter S.K. Tyring K. Gordon 2008 Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial J Am Acad Dermatol 58 106 15
43. J.H. Saurat G. Stingl L. Dubertret 2008 Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION) Br J Dermatol 158 558 66
44. A.S. Paller A.S. Paller E.C. Siegfried 2008 Etanercept treatment for children and adolescents with plaque psoriasis N Engl J Med 358 241 51
45. S.R. Rapp S.R. Feldman M.L. Exum 1999 Psoriasis causes as much disability as other major medical diseases J Am Acad Dermatol 41 401 7
46. A.Y. Finlay 2005 Current severe psoriasis and the rule of tens Br J Dermatol 152 861 7
47. L. Naldi 2008 The search for effective and safe disease control in psoriasis Lancet 371 1311 2